In a cohort study of patients with immune-mediated diseases, including psoriasis, patients on TNF inhibitor monotherapy had lower risk of COVID-19-related hospitalization or death compared to individuals on combination regimens or monotherapy with methotrexate, azathioprine/6-mercaptopurine, and Jak inhibitors [12]. The gene discussed is TNF; the disease is COVID-19.